Bengaluru, 20 December 2024: We are excited to share a major milestone at Futura Surgicare Pvt Ltd — our official entry into the United States healthcare market through a strategic partnership with Novo Integrated Sciences.
This collaboration is a significant step forward in our mission to bring high-quality, innovative medical solutions to patients across the globe. The US market, with its rigorous standards and regulatory framework, represents both a challenge and an opportunity. Navigating FDA approvals requires specialised knowledge and experience — which is why we’ve joined forces with Novo Integrated Sciences.
With Novo’s expertise in regulatory affairs, we are confident in accelerating the approval process and ensuring full compliance with US healthcare regulations. This partnership empowers us to introduce our advanced range of surgical sutures and medical devices to American healthcare professionals and institutions.
At Futura Surgicare, everything we do is rooted in excellence, innovation, and patient care. This move reflects our ongoing commitment to improving global health outcomes by delivering reliable and effective medical products.
As we embark on this exciting journey, we look forward to sharing updates and milestones along the way. Stay tuned as we bring our proven solutions to new markets — shaping the future of healthcare, one step at a time.
About Futura Medtech
Futura Medtech is a Bengaluru-based medical devices group and the group brand of Futura Surgicare Pvt Ltd. Founded in 1994, the group brings together Dolphin Sutures, Suture Planet and Rivarp Medical, covering wound closure, hernia repair, ligation, hemostasis, spine, interventional cardiology and neuromonitoring. Its products are supplied to hospitals, governments and distributors in more than 85 countries.
Media contact
hello@futuramedtech.com · +91 80 4080 2850



